Takeda Pharmaceutical Company Limited
TKPHF
$28.35
$0.672.42%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -676.88M | 155.99M | 619.28M | 611.08M | -20.33M |
| Total Depreciation and Amortization | 980.04M | 1.23B | 1.29B | 1.23B | 1.04B |
| Total Amortization of Deferred Charges | 265.19M | -- | -- | -- | 219.53M |
| Total Other Non-Cash Items | 870.57M | 552.46M | -286.00M | 467.16M | 239.06M |
| Change in Net Operating Assets | 18.85M | 582.01M | 262.22M | -1.22B | 399.99M |
| Cash from Operations | 1.46B | 2.52B | 1.89B | 1.09B | 1.88B |
| Capital Expenditure | -320.17M | -295.65M | -332.85M | -368.52M | -300.02M |
| Sale of Property, Plant, and Equipment | 210.00K | 52.50K | 195.10K | 57.70K | 13.50K |
| Cash Acquisitions | -6.59M | -- | -- | -- | -- |
| Divestitures | 450.51M | 8.26M | 36.26M | 18.87M | 132.00M |
| Other Investing Activities | -253.11M | -470.38M | -209.08M | -655.69M | -246.18M |
| Cash from Investing | -129.14M | -757.72M | -505.48M | -1.01B | -414.19M |
| Total Debt Issued | 27.49B | 40.00B | 476.82B | 507.64B | -3.00B |
| Total Debt Repaid | -230.99B | -510.88B | -546.37B | -78.03B | -11.28B |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -49.98B | 0.00 | 0.00 | -1.88B | 0.00 |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -63.90M | -953.75M | -61.89M | -886.07M | -61.48M |
| Other Financing Activities | -38.57B | -39.64B | -31.30B | 26.76B | -34.82B |
| Cash from Financing | -1.98B | -4.30B | -740.38M | 2.03B | -392.23M |
| Foreign Exchange rate Adjustments | -63.65M | 150.02M | -281.12M | 110.48M | 71.14M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -715.33M | -2.39B | 363.33M | 2.23B | 1.14B |